Nasdaq Ortx News Today

CHI Advisors LLC boosted its holdings in shares of Orchard Therapeutics plc (NASDAQ:ORTX – Free Report) by 1,529.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,315,654 shares of the company’s stock after acquiring an additional 11,559,916 shares during the quarter. Orchard Therapeutics accounts […]

Orchard Therapeutics (NASDAQ:ORTX – Get Free Report) and Immatics (NASDAQ:IMTXW – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends. Profitability This table compares Orchard Therapeutics and Immatics’ net […]

Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic...

Forefront Analytics LLC bought a new stake in Orchard Therapeutics plc (NASDAQ:ORTX – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,183 shares of the company’s stock, valued at approximately $110,000. Forefront Analytics LLC owned 0.06% […]

Forefront Analytics LLC bought a new stake in shares of Orchard Therapeutics plc (NASDAQ:ORTX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,183 shares of the company’s stock, valued at approximately $110,000. Other hedge funds have also recently bought and […]

Orchard Therapeutics (NASDAQ:ORTX – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Volatility & Risk Orchard Therapeutics has a […]

Oppenheimer restated their outperform rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $34.00 target price on the stock. Separately, Cantor Fitzgerald restated an overweight rating on shares of Orchard Therapeutics in a report on Monday, May 15th. Get Our […]

BOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, expresses its strong appreciation...

Orchard Therapeutics (NASDAQ:ORTX – Get Free Report) and Peak Bio (NASDAQ:PKBO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Earnings & Valuation This table compares Orchard […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Free Report) shares were up 0.4% during mid-day trading on Tuesday . The company traded as high as $5.20 and last traded at $5.11. Approximately 13,587 shares changed hands during trading, a decline of 83% from the average daily volume of 78,334 shares. The stock had previously closed at […]